Triptans in Patients with Cardiovascular Risks

Medication Talk

Headache medicine specialist Rebecca C. Burch, MD, joins us to talk about triptan use in patients with cardiovascular risk factors.
Listen in as they clear up confusion about which patients should avoid triptans due to cardiovascular concerns.
You’ll also hear practical advice from panelists on TRC’s Editorial Advisory Board:

• Anthony A. Donato, Jr., MD, MHPE, Associate Program Director, Internal Medicine from the Reading Health System, and Professor of Medicine at the Sidney Kimmel Medical College at Thomas Jefferson University
• Steven E. Nissen, MD, MACC, the Chief Academic Officer at the Heart and Vascular Institute and the Lewis and Patricia Dickey Chair in Cardiovascular Medicine Professor of Medicine at the Cleveland Clinic Lerner School of Medicine at Case Western Reserve University
• Joseph Scherger, MD, MPH, Family Physician, Primary Care 365, Eisenhower Health
• Craig D. Williams, PharmD, FNLA, BCPS, Clinical Professor, Department of Pharmacy Practice at the Oregon Health and Science University

For the purposes of disclosure, Dr. Steven Nissen reports a relevant financial relationship with AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Esperion, Medtronic, Novartis, Pfizer, Silence Therapeutics (grants/research support). The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.

Pharmacist’s Letter offers CE credit for this podcast. Log in to your Pharmacist’s Letter account and look for the title of this podcast in the list of available CE courses.
Claim Credit

If you’re not yet a Pharmacist’s Letter or Prescriber Insights subscriber, find out more about our product offerings at trchealthcare.com.
Follow or subscribe, rate, and review this show in your favorite podcast app. Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.
You can also reach out to provide feedback or make suggestions by emailing us at [e-mail].